Onset Therapeutics Launches BENZEFOAM ™ Emollient Foam for Body Acne

Onset Therapeutics, a specialty pharmaceutical company focused on dermatology, announced today the commercial availability of BenzEFoam ™ (benzoyl peroxide) 5.3% Emollient Foam, the first prescription foam formulation of benzoyl peroxide. BenzEFoam ™ Emollient Foam is indicated for the topical treatment of mild to moderate acne vulgaris.
BenzEFoam ™ Emollient Foam is formulated to address the needs of patients with body acne and to offer an ideal treatment option for them. BenzEFoam ™ is easily spread over the extensive areas of the skin chest and back, where body acne symptoms most often occur. BenzEFoam ™ has demonstrated low rates of cutaneous irritation and dryness in clinical trials.
BenzEFoam Emollient Foam ™ is proven to be very effective in reducing the acne-causing bacteria P. acnes on the back. In a clinical trial, BenzEFoam demonstrated a greater than 100-fold reduction in P. acnes counts after two weeks of use. "Benzoyl peroxide is a mainstay of acne treatment. Dermatologists have been waiting for a foam formulation of benzoyl peroxide, "said Dr. Hilary Baldwin, Vice Chair and Associate Professor, Department of Dermatology, State University of New York (SUNY), Brooklyn. "We believe patients prefer and are more compliant with applying foam formulations for skin conditions affecting broad body areas. BenzEFoam ™ is a good treatment option for chest and back acne, as well as for acne in hairy areas. "

"We are excited to bring BenzEFoam Emollient Foam ™ as a new body acne treatment option to dermatologists and their patients," stated Doug Abel, General Manager of Onset Therapeutics. "We believe this is a topical therapy Which May Improve Outcomes in patients with acne appearing on the chest and back Because it is effective, well tolerated, and easy to spread over these larger areas." "The development of the first prescription benzoyl peroxide emollient foam is a major accomplishment for Onset Therapeutics," said Michael Heffernan, President of Onset Therapeutics. "The clinical results combined with the feedback from dermatologists confirm our strong belief in the value of the DELEVO ™ Foam Technology and its applicability to many different active ingredients for the Treatment of Dermatologic Conditions. The launch of BenzEFoam Emollient Foam ™, our second major product launch this year along with Hylatopic Emollient Foam ™, is a testament to our product development team and the extensive product pipeline that they have developed. "

BenzEFoam Emollient Foam ™ is currently available through all major drug wholesalers.
Acne vulgaris is a common skin disease, affecting 40 to 50 million Americans. Approximately 50% of all acne patients have both facial and non facial acne symptoms. In the U.S. in the past year, five more than one million patients with acne Sought treatment from a physician, Resulting in over 17 million prescriptions filled, according to data from Verispan and IMS. Indication and Important Safety Information for BenzEFoam Emollient Foam ™
BenzEFoam ™ (benzoyl peroxide) 5.3% Emollient Foam is indicated for use in the topical treatment of mild to moderate acne vulgaris. BenzEFoam Emollient Foam should not be used in patients who have shown hypersensitivity to benzoyl peroxide or to any of the other ingredients in the product. Allergic contact dermatitis and dryness have been reported with topical benzoyl peroxide therapy. When using this product, avoid unnecessary sun exposure and use a sunscreen. BenzEFoam, like all products containing benzoyl peroxide, may bleach hair or colored fabrics. Onset Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of dermatology products formulated with the Company's innovative proprietary topical formulation technologies and unique delivery systems. The Company utilizes its novel DELEVO Foam Technology ™ that is designed to deliver enhanced penetration of active ingredients proven in cosmetically elegant, hydrating formulation with the goal of enhancing patient compliance.